Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity

Cited by (219)

Items 201–219 of 219

1. Targeted degrader conjugates (TDCs): Modalities for precision delivery of PROTACs and molecular glue degraders
   Xiaolei Meng, Mengjun Ma, Xiao Wang, Shumin Ma, Zhuoyue Li, Tingting Wu, Shaomeng Wang, Chong Qin · 2026 · Acta Pharmaceutica Sinica B
2. Expanding the E3 Ligase Landscape: From Small Molecule to Biological Targeted Protein Degradation
   Xuan Zhao, Yuhan Liu, Xucong Teng · 2026 · Handbook of experimental pharmacology
3. Impact of time and temperature on glycation, oxidation, and functional stability of trastuzumab deruxtecan (ENHERTU®) in dextrose infusion bags
   E. Hindes, Victor Cochard, Salma Fourati, Yara Mayssa Bendiab, Clara Juul, Dominique Combeau, Najet Yagoubi, Guillaume Chevreux, Marie Antignac, Hassane Sadou Yayé · 2026 · European Journal of Pharmaceutical Sciences
4. In vivo fate-guided design of efficient delivery systems for PROTACs: From molecular rationales to clinical progress
   Wei Zhang, Shiyuan Li, Yao Yao, Yuling Mao, WenJun Jiang, Shuai Li · 2026 · Pharmacological Research
5. Integrating a Tumor Size‐Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody‐Drug Conjugates in Non‐Small Cell Lung Cancer
   Mehdi Nikfar, Richard C. Franzese, Herbert Struemper, Brett A. Howell, Murad R. Melhem · 2026 · CPT Pharmacometrics & Systems Pharmacology
6. Degradation-coupled antibody conjugates for precision cancer therapy
   Xinlei Zhuang, Li Lin, Yiyi Zhang, Yifan Wang, Liqiang Pan · 2026 · Trends in Molecular Medicine
7. Investigation of the pharmacokinetics, metabolism, and clearance pathways of a heterobifunctional BRM degrader delivered by a TROP2-targeting antibody
   Joyce Liu, Shu Chen, Yi-Chen Chen, Yusi Cui, Martine Darwish, Summer A. Baker Dockrey, Geoffrey Del Rosario, Peter S. Dragovich, Liling Liu, Li Ma et al. · 2026 · Drug Metabolism and Disposition
8. BindingDB Entry 50019272: Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.
   BindingDB · 2024 · UC San Diego
9. BindingDB Entry 50021145: Annual review of PROTAC degraders as anticancer agents in 2022.
   BindingDB · 2025 · UC San Diego
10. BindingDB Entry 50018681: A comprehensive review of BET-targeting PROTACs for cancer therapy.
    BindingDB · 2024 · UC San Diego
11. BindingDB Entry 50020200: Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates.
    BindingDB · 2024 · UC San Diego
12. BindingDB Entry 50019285: Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines.
    BindingDB · 2024 · UC San Diego
13. BindingDB Entry 50022138: Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
    BindingDB · 2025 · UC San Diego
14. BindingDB Entry 50018114: Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation.
    BindingDB · 2024 · UC San Diego
15. BindingDB Entry 50023360: PROTAC technology: From drug development to probe technology for target deconvolution.
    BindingDB · 2026 · UC San Diego
16. BindingDB Entry 50020203: Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues.
    BindingDB · 2024 · UC San Diego
17. BindingDB Entry 50020717: A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.
    BindingDB · 2024 · UC San Diego
18. BindingDB Entry 50021132: Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    BindingDB · 2025 · UC San Diego
19. Targeted protein degradation in cancer: strategies for undruggable targets and progress towards clinical translation
    Jinxin Tang, Zehao Cheng, Tian Xie, Yan Zhuang, Hongkun Hu, Chenbei Li, Hua Wang, Chengyao Feng, Chao Tu · 2026 · Biomarker Research